Month: February 2010

Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering

CRANBURY, N.J., Feb. 25 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered into definitive agreements with certain accredited investors to sell in a registered direct offering 9.6 million units at a price of $0.27 per unit for gross proceeds of $2.6 million, before deducting placement agent fees and other …

Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering Read More »

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010

CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its second quarter ended December 31, 2009.  Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 Read More »

Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men

CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction.  The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 …

Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men Read More »

Scroll to Top